Application of human leucocyte interferon in patients with urinary bladder papillomatosis, breast cancer, and melanoma.
Eight patients with malignant papillomaosis of the bladder, four with breast cancer, and two with malignant melanoma, all of whom had a poor prognosis, were treated with injection of crude human leucocyte interferon (HLI) into the tumour or the adjacent tissue and in some cases with intramuscular HLI injection also. All tumours showed complete or partial regression after treatment for up to 6 months. One patient with breast cancer died from distant metastases; all other patients in the trial were recurrence-free after 3--30 months of follow-up.
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000628:therapy*; D005260:Female; D006801:Humans; D007372:Interferons / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008545:Melanoma / Q000628:therapy*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010212:Papilloma / Q000628:therapy*; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D007372:Interferons